Myoview (Tetrofosmin)

Tetrofosmin, the active ingredient in Myoview, is a radiopharmaceutical presented as an injectable solution for intravenous use. It enables visualization of myocardial blood flow, supporting diagnosis of coronary artery disease, assessment of myocardial viability, and perfusion imaging in patients undergoing cardiac evaluation and stress testing.

GNH USA supplies Myoview as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, cardiac centers, and diagnostic imaging facilities worldwide, ensuring reliable global distribution and regulatory compliance. The product complies with EU pharmacopeial standards and is available for export to international markets.

Myoview (tetrofosmin) is used in cardiac imaging to assess myocardial perfusion and viability.

Myocardial perfusion imaging: provides quantitative assessment of blood flow to detect regional ischemia. Coronary artery disease detection: helps identify obstructive lesions by highlighting perfusion defects. Myocardial viability evaluation: distinguishes viable from scarred myocardium to guide revascularization decisions.

Adverse reactions to Myoview are generally infrequent but may occur following intravenous administration.

Common Side Effects: - Nausea: mild transient nausea reported after injection. - Headache: occasional headache during or after the procedure. - Flushing: transient facial or upper body flushing. - Injection site pain: mild discomfort at the venous access site.

Serious or Rare Side Effects: - Anaphylactic reaction: rare severe allergic response requiring immediate medical intervention. - Hypotension: sudden drop in blood pressure that may need monitoring. - Cardiac arrhythmia: rare occurrence of abnormal heart rhythm during imaging.

Prior to Myoview administration, clinicians should evaluate patient-specific factors and follow handling guidelines.

Pregnancy: unknown risk; avoid use unless clearly needed. Breastfeeding: unknown safety; consider discontinuation during treatment. Renal impairment: use with caution as clearance may be reduced. Hypersensitivity: assess for prior reactions to radiopharmaceuticals. Concomitant radiotracers: avoid overlapping administration of other nuclear medicine agents. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Myoview may interact with other agents that affect myocardial blood flow or imaging quality.

Major Interactions (Avoid): - Concurrent myocardial perfusion agents: may interfere with image interpretation. - Iodinated contrast media within 24 h: can alter tracer distribution and reduce image quality.

Moderate Interactions (Monitor Closely): - Beta‑blockers: can modify myocardial blood flow and affect tracer uptake. - Calcium channel blockers: may influence perfusion patterns. - Caffeine intake: can diminish tracer uptake if consumed within 12 h before imaging. - Antihistamines: may mask mild allergic reactions.